Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TNF | P01375 | 1/20 | 0.44 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6370607 | 0.79 | CA2 (0.52) | KMT2AKDM4ELMNANFE2L2 | |
| SCHEMBL8765692 | 0.77 | ALDH1A1 (0.34) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL15624412 | 0.76 | TRPV1 (0.47) | EPHX2TRPV1 | |
| SCHEMBL31009386 | 0.74 | EPHX2 (0.44) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL31608519 | 0.74 | EPHX2 (0.44) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL8436654 | 0.74 | EPHX2 (0.44) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL610024 | 0.74 | EPHX2 (0.44) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL11972375 | 0.74 | CA2 (0.37) | KMT2AKDM4E | |
| SCHEMBL8138183 | 0.74 | CNR2 (0.41) | MEN1TNFCXCL8KMT2APAX8 | |
| SCHEMBL162911 | 0.73 | EPHX2 (0.43) | MEN1TNFCXCL8KMT2APAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 547 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113248424-A | Novel microchannel preparation process of 2-hydroxy-3-trifluoromethyl-5-nitropyridine | 甘肃安卓幸制药有限公司 | 2021-08-13 | — | — | CN | claimed |
| CN-112441966-A | Method for producing 2-chloro-3-trifluoromethylpyridine from 2,3, 6-trichloro-5-trifluoromethylpyridine | 山东省农药科学研究院 | 2021-03-05 | — | — | CN | claimed |
| CN-111269205-A | Preparation method of C-aryl glycoside compound | 华侨大学 | 2020-06-12 | — | — | CN | claimed |
| CN-110256184-A | A kind of three replace the preparation method of connection ene derivative | 华侨大学 | 2019-09-20 | — | — | CN | claimed |
| CN-109879899-A | A kind of preparation method of trans- three substituted olefines derivative | 华侨大学 | 2019-06-14 | — | — | CN | claimed |
| CN-109021003-A | A kind of vinyl silicon germanium stannane derivative preparation method | 华侨大学 | 2018-12-18 | — | — | CN | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | claimed |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-29 | — | — | US | claimed |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-22 | — | — | US | claimed |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-05-08 | — | — | US | claimed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | claimed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | claimed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | claimed |
| EP-1115693-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL $i(TERTIARY)-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | Monsanto Company (US) | 2001-07-18 | — | — | EP | claimed |
| WO-2000018721-A1 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL TERTIARY-HETEROALKYLAMINES USEFUL FOR INHIBITING CHOLESTERYL ESTER TRANSFER PROTEIN ACTIVITY | MONSANTO COMPANY (US) | 2000-04-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MEN1 4599/4885TNF 4509/4885CXCL8 3417/4885 |
| US-20030096818-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MEN1 4599/4885TNF 4509/4885CXCL8 3417/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | MEN1 4618/4885TNF 4440/4885CXCL8 3101/4885 |
| US-20030087905-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MEN1 4599/4885TNF 4509/4885CXCL8 3417/4885 |
| US-20030100559-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MEN1 4599/4885TNF 4509/4885CXCL8 3417/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | MEN1 4599/4885TNF 4509/4885CXCL8 3417/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | MEN1 3887/4885TNF 4524/4885CXCL8 4100/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | MEN1 4595/4885TNF 4211/4885CXCL8 2687/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | MEN1 2591/4885TNF 2801/4885CXCL8 1979/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.